A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

Recruiting

Phase 1

Phase 2

REGN5668, Cemiplimab & REGN4018A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT04590326

Conditions

Ovarian Cancer

Fallopian Tube Cancer

Primary Peritoneal Cancer

Endometrial Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

REGN5668

Cemiplimab

REGN4018

Sarilumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2025-04-10.